GPT and metabolic dysfunction-associated steatotic liver disease: As anticipated, both metabolites significantly attenuated HFD‐induced NAFLD progression, evidenced by improved serum profiles: reduced total cholesterol (TC), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels (Figure 8J,K).